The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas

BACKGROUND: Spinal neurofibromas (SNFs) in neurofibromatosis type 1 (NF1) can cause progressive spinal cord compression and neurological dysfunction. The MEK inhibitor selumetinib shrinks the majority of plexiform neurofibromas (PNs) in patients with NF1. We assessed the effect of selumetinib on SNF...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neurooncol Adv
Prif Awduron: Jackson, Sadhana, Baker, Eva H, Gross, Andrea M, Whitcomb, Patricia, Baldwin, Andrea, Derdak, Joanne, Tibery, Cecilia, Desanto, Jennifer, Carbonell, Amanda, Yohay, Kaleb, O’Sullivan, Geraldine, Chen, Alice P, Widemann, Brigitte C, Dombi, Eva
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2020
Pynciau:
Clinical Investigations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7486535/
https://ncbi.nlm.nih.gov/pubmed/32939452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa095
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg